On May 27, 2021, Cravath was honored as the 2021 “Antitrust Law Firm of the Year” at the Chambers USA 2021 Awards, which took place at a virtual ceremony. The Chambers USA awards recognize preeminence in key practice areas based on research of notable achievements over the past year, including outstanding work, impressive strategic growth and excellence in client service. Cravath’s antitrust work in the past year included securing a complete defense victory for Qualcomm at the Ninth Circuit, which confirmed the lawfulness of Qualcomm’s business model and vacated a worldwide, permanent injunction against the company; representing Mylan N.V. in connection with its $50 billion combination with Upjohn to form Viatris Inc., a new global pharmaceutical company; and representing Epic Games in separate actions against Apple and Google alleging that the companies are engaged in anticompetitive behavior in the distribution of certain apps on smartphones and in the processing of in‑app purchases.
Related Practices & Industries
Related News & Insights
Deals & Cases
August 13, 2020
Qualcomm Wins on Appeal Against FTC in Antitrust Suit
On August 11, 2020, the United States Court of Appeals for the Ninth Circuit ruled in favor of Cravath client Qualcomm Incorporated, a leading innovator of cellular technology, in its appeal from an adverse California federal court decision in an antitrust lawsuit filed by the Federal Trade Commission (“FTC”). In a complete defense victory for Qualcomm, the three‑judge panel for the Ninth Circuit unanimously reversed the district court’s judgment and vacated a permanent, worldwide injunction that prohibited several of Qualcomm’s core business practices.
Deals & Cases
July 29, 2019
Mylan’s $50 Billion Combination with Upjohn, a Division of Pfizer
On July 29, 2019, Mylan N.V. and Pfizer Inc. announced a definitive agreement to combine Mylan with Upjohn, Pfizer's off-patent branded and generic established medicines business, creating a new global pharmaceutical company. Under the terms of the agreement, which is structured as an all-stock, Reverse Morris Trust transaction, each Mylan share would be converted into one share of the new company. Pfizer shareholders would own 57% of the combined new company, and Mylan shareholders would own 43%. Cravath is representing Mylan in connection with the transaction.
Cravath Bicentennial
Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.
Attorney Advertising. ©2025 Cravath, Swaine & Moore LLP.